2019-04-01 08:28:00 Mon ET
technology social safety nets education infrastructure health insurance health care medical care medication vaccine social security pension deposit insurance
OraSure and its subsidiary DNA Genotek specialize in the lean production of home DNA spit tubes. OraSure extracts core genetic information from microbiome saliva samples and then provides discreet DNA diagnostic test tubes and kits for liquid biopsy, hepatitis, cancer, and HIV etc. In the meantime, OraSure and its subsidiary DNA Genotek serve as a quasi-monopoly with secure economic rent protection in the new biotech market for DNA spit tubes.
As there has been a substantial increase in international demand for cost-effective and affordable DNA tests over the past decade, OraSure gains much from its R&D-driven royalty revenue. As of April 2019, the small-cap stock OraSure trades at a P/E ratio of 16.6x near most long-term average stock market benchmarks. Further, the current stock market capitalization of OraSure is almost 3.4x times total sales and 2.2x times total book assets. From a fundamental perspective, OraSure enjoys juicy profit margins: the gross profit margin of 62.5% exceeds most stock market benchmarks, and the net profit margin hovers in the healthy range of 11%-15% in recent times. As its broad biotech patents and trademarks represent fundamental competitive moats and niches, OraSure continues to dominate in the new specialty market for DNA diagnostic test tubes.
If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.
2025-10-31 12:26:00 Friday ET

With respect to wider weight loss treatment and obesity treatment, the global market for GLP-1 medications now grows substantially to benefit more than 1 bi
2023-11-28 11:35:00 Tuesday ET

David Colander and Craig Freedman argue that economics went wrong when there was no neoclassical firewall between economic theories and policy reforms. D
2018-11-23 09:39:00 Friday ET

Former White House chief economic advisor Gary Cohn points out that there is no instant cure for the Sino-U.S. trade dilemma. After the U.S. midterm electio
2016-10-01 00:00:00 Saturday ET

We can learn much from the frugal habits and lifestyles of several billionaires on earth. Warren Buffett, Chairman and CEO of Berkshire Hathaway, still l
2018-03-27 07:33:00 Tuesday ET

CNBC's business anchorwoman Becky Quick interviews Nobel Laureate Joseph Stiglitz on the current trade war between America and China. As America imposes
2017-02-01 14:41:00 Wednesday ET

President Trump refreshes his public image through his presidential address to Congress with numerous ambitious economic policies in order to make America g